Literature DB >> 20103616

Stability of cyclophosphamide in extemporaneous oral suspensions.

Rachel Kennedy1, Daniel Groepper, Michael Tagen, Robbin Christensen, Fariba Navid, Amar Gajjar, Clinton F Stewart.   

Abstract

BACKGROUND: Cyclophosphamide, an alkylating agent, is widely used for the treatment of many adult and pediatric malignancies. The stability of cyclophosphamide in aqueous- and methylcellulose-based oral suspending vehicles is currently unknown.
OBJECTIVE: To develop and validate a stability-indicating high-performance liquid chromatography (HPLC) method to measure cyclophosphamide concentrations in simple syrup and Ora-Plus, and assess the 56-day chemical stability and physical appearance of cyclophosphamide in these suspensions at both room temperature (22 degrees C) and 4 degrees C.
METHODS: The intravenous formulation of cyclophosphamide was diluted to 20 mg/mL in NaCl 0.9%, compounded 1:1 with either suspending vehicle, and stored in the dark in 3-mL amber polypropylene oral syringes at 4 degrees C and 22 degrees C. Aliquots from each syringe were obtained on days 0, 3, 7, 14, 21, 28, 35, 42, 49, and 56 and assayed using the validated stability-indicating HPLC-UV method. A C18 analytical column was used to separate cyclophosphamide from the internal standard, ifosfamide, with a mobile phase of 21% acetonitrile in 79% sodium phosphate buffer. The suspension was examined for odor change, visually examined under normal fluorescent light for color change, and examined under a light microscope for evidence of microbial growth.
RESULTS: Samples of cyclophosphamide in both simple syrup and Ora-Plus were stable when kept at 4 degrees C for at least 56 days. At room temperature, cyclophosphamide in simple syrup and Ora-Plus had a shelf life of 8 and 3 days, respectively. No changes in color or odor or evidence of microbial growth were observed.
CONCLUSIONS: Cyclophosphamide can be extemporaneously prepared in simple syrup or Ora-Plus and stored for at least 2 months under refrigeration without significant degradation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20103616      PMCID: PMC2835970          DOI: 10.1345/aph.1M578

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  23 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic.

Authors:  R S Kerbel; G Klement; K I Pritchard; B Kamen
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

Review 3.  Cyclophosphamide and related anticancer drugs.

Authors:  F Baumann; R Preiss
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-11-25

4.  Chemical stability of cyclophosphamide in aromatic elixir USP.

Authors:  D Brooke; R E Davis; R J Bequette
Journal:  Am J Hosp Pharm       Date:  1973-07

5.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.

Authors:  M Colleoni; A Rocca; M T Sandri; L Zorzino; G Masci; F Nolè; G Peruzzotti; C Robertson; L Orlando; S Cinieri; Braud F de; G Viale; A Goldhirsch
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

6.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Authors:  T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

7.  A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.

Authors:  Urban Emmenegger; Shan Man; Yuval Shaked; Giulio Francia; John W Wong; Daniel J Hicklin; Robert S Kerbel
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags.

Authors:  Cedric Menard; Celine Bourguignon; Joël Schlatter; Norbert Vermerie
Journal:  Ann Pharmacother       Date:  2003-12       Impact factor: 3.154

9.  Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.

Authors:  Daniel C Bowers; Victor M Aquino; Patrick J Leavey; Robert O Bash; Janna M Journeycake; Gail Tomlinson; Arlynn F Mulne; Heidi J Haynes; Naomi J Winick
Journal:  Pediatr Blood Cancer       Date:  2004-01       Impact factor: 3.167

Review 10.  Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses.

Authors:  A R Ahmed; S M Hombal
Journal:  J Am Acad Dermatol       Date:  1984-12       Impact factor: 11.527

View more
  2 in total

1.  Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.

Authors:  Sara M Federico; Kenneth J Caldwell; Mary B McCarville; Vinay M Daryani; Clinton F Stewart; Shenghua Mao; Jianrong Wu; Andrew M Davidoff; Victor M Santana; Wayne L Furman; Alberto S Pappo; Fariba Navid
Journal:  Eur J Cancer       Date:  2020-04-20       Impact factor: 9.162

2.  Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update.

Authors:  Richard H Parrish; Lisa D Ashworth; Raimar Löbenberg; Sandra Benavides; Jeffrey J Cies; Robert B MacArthur
Journal:  Pharmaceutics       Date:  2022-05-10       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.